{
  "ticker": "CAI",
  "trade_date": "2025-08-13",
  "execution_time": 86.772655,
  "timestamp": "2025-08-13T18:51:40.509044",
  "final_decision": "BUY",
  "investment_plan": "Below is our comprehensive investment plan for Caris Life Sciences Inc (CAI), derived from a synthesis of technical data, fundamentals, sentiment, and the final debate positions.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Investment Recommendation  \n\u2022 Recommendation: BUY, but with a partial hedge.  \n\u2022 Confidence Level: Moderately bullish (~70/100) given the strong sentiment and upside price targets, while acknowledging near\u2010term uncertainties raised by our bearish counterpart.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Position Sizing  \n\u2022 Recommended Allocation: 5\u201310% of your portfolio.  \n\u2022 Rationale: Given the mixed fundamental \u201chold\u201d signal and technical neutrality combined with bullish sentiment, a moderate allocation minimizes exposure if near\u2010term risks materialize.  \n\u2022 Hedge: Use options or a short position in a correlated biotech ETF on a small portion (e.g., 10\u201320% of the CAI position) to protect against a sudden downside move.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Entry Strategy  \n\u2022 Target Entry Price: Aim to accumulate positions on dips around $33\u2013$33.50\u2014just below the current price of $34.28\u2014to improve yield of potential upside.  \n\u2022 Entry Conditions:  \n\u2003\u2013 Look for an intraday pullback or consolidation area before a breakout higher.  \n\u2003\u2013 Confirm with any renewed technical momentum (attempting to shift from \u201chold\u201d to \u201cbuy\u201d indicators).  \n\u2013 Alternatively, consider staged entries rather than a lump sum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Risk Management  \n\u2022 Stop-Loss Level: Set a stop-loss around 10% below the entry price (approximately $30\u2013$30.50) to limit losses if fundamentals or market sentiment shift negatively.  \n\u2022 Hedging:  \n\u2003\u2013 Implement a protective put or a call spread hedge on a portion of your CAI position to guard against near-term volatility.  \n\u2003\u2013 Monitor short-term technical signals and quarterly disclosure updates to adjust the hedge as needed.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n5. Time Horizon  \n\u2022 Medium-Term Outlook: Hold for a period of several weeks to a few months.  \n\u2022 Rationale: This horizon captures potential upward moves toward the mean target of ~$41 while allowing time to assess quarterly results and regulatory updates before any longer-term re-rating.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n6. Key Catalysts  \n\u2022 Positive Quarterly Earnings: Better-than-expected outlook or growth news could fuel further buying.  \n\u2022 Regulatory or Clinical Developments: Progress in precision oncology therapies that validate CAI\u2019s technology.  \n\u2022 Continued Positive Market Sentiment: Sustained bullish engagement on platforms like StockTwits or favorable analyst upgrades may support upward price movement.  \n\u2022 Index Inclusion: Having been added to the NASDAQ Composite Index may steadily enhance liquidity and investor attention.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n7. Major Risks  \n\u2022 Structural and Fundamental Risks: Regulatory setbacks, disappointing clinical trial outcomes, or management changes could trigger a re-rating downward.  \n\u2022 Near-Term Volatility: The bearish argument warns of a short squeeze and near-term pressures; adverse quarterly disclosures may accelerate selling.  \n\u2022 Market Environment: A broader biotech slowdown or shifts in market risk sentiment could impose downside risk.\n  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n8. Synthesis and Final Decision  \n\u2022 Bull Perspective: Emphasizes that CAI\u2019s latent value and a strong margin of safety\u2014supported by a mean target of ~$41 and an overall bullish sentiment score\u2014make it an attractive buy in today\u2019s dynamic biotech sector.  \n\u2022 Bear Perspective: Cautions that near-term risks (such as potential short squeezes and structural concerns) justify using hedges and cautious position sizing.  \n\u2022 Final Decision: By blending these views, our strategy is to go long on CAI with a \u201cbuy-with-hedge\u201d approach. This allows you to participate in the upside suggested by bullish sentiment and technical targets while protecting downside risk in case near-term catalysts go against expectations.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nActionable Summary:  \n\u2022 Initiate a 5\u201310% portfolio allocation in CAI, entering incrementally at dips around $33\u2013$33.50.  \n\u2022 Place a stop-loss near $30 to control risk and hedge a fraction (10\u201320% of the position) with options to safeguard against volatility.  \n\u2022 Maintain a medium-term view (a few weeks to months) and closely monitor quarterly results, regulatory updates, and market sentiment for adjustments.\n\nThis balanced, tactical plan seeks to capture potential appreciation while cushioning the portfolio from near-term structural uncertainties.",
  "full_result": {
    "company_of_interest": "CAI",
    "trade_date": "2025-08-13",
    "step": "aggregation_complete",
    "market_report": "\ud83d\udcca TECHNICAL ANALYSIS: CAI\n\u26a1 Indicators calculated in 0.000s (Async Ultra-Fast Mode)\n============================================================\n\n\ud83d\udcc8 CURRENT PRICE ACTION:\n  Price: $34.28\n  Volume: 1,833,100\n  Day Range: $33.02 - $39.80\n\n============================================================\n\ud83d\udd0d TECHNICAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed technical signals\n  \u26a0\ufe0f Limited indicator data available\n\n\u26a1 Report generated 2025-08-13 18:50:16\n\ud83d\udcca Total indicators analyzed: 0",
    "news_report": "# NEWS DATA COLLECTION - CAI\n\nGenerated: 2025-08-13 18:50:25\nTrade Date: 2025-08-13\n\n## COLLECTION METRICS\n- Total Articles: 50\n- Serper: 50 articles\n- Finnhub: 0 articles\n- Collection Time: 8.549s\n\n## RAW ARTICLE DATA\n\n### Article 1\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: hace 2 d\u00edas\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 2\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: hace 13 horas\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 3\nTitle: Here's Why Cairo Communication (BIT:CAI) Can Manage Its Debt Responsibly\nSource: Simply Wall Street\nDate: 10 may 2025\nURL: https://simplywall.st/stocks/it/media/bit-cai/cairo-communication-shares/news/heres-why-cairo-communication-bitcai-can-manage-its-debt-res-1\nContent: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices,...\n\n### Article 4\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: hace 1 mes\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ended up debuting far above its...\n\n### Article 5\nTitle: CAI Stock Debut: Caris Life Sciences IPO Explained\nSource: www.tradingcalendar.com\nDate: 9 jun 2025\nURL: https://www.tradingcalendar.com/post/cai-ipo\nContent: Caris Life Sciences is making its market debut with a substantial public offering designed to fuel its ambitious plans in precision oncology.\n\n### Article 6\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 18 jun 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Caris Life Sciences (NASDAQ:CAI) shares traded higher after it opened well above its initial public offering price on Wednesday as the...\n\n### Article 7\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 18 jun 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 8\nTitle: 3 Reasons KAI is Risky and 1 Stock to Buy Instead\nSource: Yahoo Finance\nDate: 18 may 2025\nURL: https://finance.yahoo.com/news/3-reasons-kai-risky-1-040057679.html\nContent: Over the past six months, Kadant's shares (currently trading at $326.02) have posted a disappointing 17.6% loss while the S&P 500 was flat.\n\n### Article 9\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 18 jun 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 10\nTitle: Caris Life Sciences, Inc.(NasdaqGS: CAI) added to NASDAQ Composite Index\nSource: MarketScreener\nDate: hace 1 mes\nURL: https://www.marketscreener.com/quote/stock/CARIS-LIFE-SCIENCES-INC-190389952/news/Caris-Life-Sciences-Inc-NasdaqGS-CAI-added-to-NASDAQ-Composite-Index-50295384/\nContent: Caris Life Sciences, Inc. has been added in the NASDAQ Composite Index. \u00a9 S&P Capital IQ - 2025 Share Latest news about Caris Life Sciences, Inc.\n\n### Article 11\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 12\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 13\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 14\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 15\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 16\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 17\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 18\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 19\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 20\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 21\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 22\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 23\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 24\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 25\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 26\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 27\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 28\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 29\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 30\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 31\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 32\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 33\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 34\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 35\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 36\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 37\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 38\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 39\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 40\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 41\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 42\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 43\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 44\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 45\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 46\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 47\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 48\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 49\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 50\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n## STRUCTURED DATA\n\n```json\n{\n  \"company\": \"CAI\",\n  \"date\": \"2025-08-13\",\n  \"total\": 50,\n  \"articles\": [\n    {\n      \"index\": 1,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"hace 2 d\\u00edas\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 2,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"hace 13 horas\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 3,\n      \"api_source\": \"serper\",\n      \"title\": \"Here's Why Cairo Communication (BIT:CAI) Can Manage Its Debt Responsibly\",\n      \"source\": \"Simply Wall Street\",\n      \"date\": \"10 may 2025\",\n      \"url\": \"https://simplywall.st/stocks/it/media/bit-cai/cairo-communication-shares/news/heres-why-cairo-communication-bitcai-can-manage-its-debt-res-1\",\n      \"full_content\": \"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices,...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 4,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"hace 1 mes\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ended up debuting far above its...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 5,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI Stock Debut: Caris Life Sciences IPO Explained\",\n      \"source\": \"www.tradingcalendar.com\",\n      \"date\": \"9 jun 2025\",\n      \"url\": \"https://www.tradingcalendar.com/post/cai-ipo\",\n      \"full_content\": \"Caris Life Sciences is making its market debut with a substantial public offering designed to fuel its ambitious plans in precision oncology.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 6,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ:CAI) shares traded higher after it opened well above its initial public offering price on Wednesday as the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 7,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 8,\n      \"api_source\": \"serper\",\n      \"title\": \"3 Reasons KAI is Risky and 1 Stock to Buy Instead\",\n      \"source\": \"Yahoo Finance\",\n      \"date\": \"18 may 2025\",\n      \"url\": \"https://finance.yahoo.com/news/3-reasons-kai-risky-1-040057679.html\",\n      \"full_content\": \"Over the past six months, Kadant's shares (currently trading at $326.02) have posted a disappointing 17.6% loss while the S&P 500 was flat.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 9,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 10,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences, Inc.(NasdaqGS: CAI) added to NASDAQ Composite Index\",\n      \"source\": \"MarketScreener\",\n      \"date\": \"hace 1 mes\",\n      \"url\": \"https://www.marketscreener.com/quote/stock/CARIS-LIFE-SCIENCES-INC-190389952/news/Caris-Life-Sciences-Inc-NasdaqGS-CAI-added-to-NASDAQ-Composite-Index-50295384/\",\n      \"full_content\": \"Caris Life Sciences, Inc. has been added in the NASDAQ Composite Index. \\u00a9 S&P Capital IQ - 2025 Share Latest news about Caris Life Sciences, Inc.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 11,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 12,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 13,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 14,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 15,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 16,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 17,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 18,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 19,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 20,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 21,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 22,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 23,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 24,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 25,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 26,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 27,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 28,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 29,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 30,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 31,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 32,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 33,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 34,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 35,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 36,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 37,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 38,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 39,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 40,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 41,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 42,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 43,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 44,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 45,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 46,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 47,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 48,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 49,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 50,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    }\n  ]\n}\n```\n",
    "sentiment_report": "### Analysis of Social Media Data for CAI\n\n#### 1. Overall Sentiment Score:\nGiven the sentiment data from the available sources (Twitter and StockTwits):\n- **Twitter Sentiment Score:** 1.0 (bullish)\n- **StockTwits Sentiment Score:** 1.0 (bullish)\n\nCalculating the overall sentiment score:\n- Average sentiment score = (1.0 + 1.0) / 2 = **1.0** \n\n**Overall Sentiment Score: 1.0**\n\n#### 2. Confidence Level:\n- Twitter has low confidence due to only 1 mention and unknown source.\n- StockTwits has high confidence based on 30 messages, with 63.3% being bullish.\n\nGiven the data limitations from Twitter, the overall confidence level is adjusted:\n**Confidence Level: Medium**\n\n#### 3. Sentiment Trend:\nTo determine trend, we consider the bullish sentiment on StockTwits (63.3% bullish and 0% bearish) and the single bullish mention on Twitter. Since both platforms indicate bullish sentiment, we can conclude that sentiment is likely stable.\n\n**Sentiment Trend: Stable**\n\n#### 4. Top 3 Key Insights:\n1. **Predominantly Bullish Sentiment:** Both platforms that provided data reflect a strong bullish sentiment towards CAI, with a high sentiment score.\n2. **High Activity on StockTwits:** StockTwits shows a significant number of messages (30), indicating higher engagement and sentiment confidence, while Twitter only has 1 mention.\n3. **Lack of Data from Reddit:** No data was available from Reddit, which limited the ability to capture a broader market sentiment regarding CAI.\n\n#### 5. Trading Signal:\nGiven the overall bullish sentiment across both engaged platforms and the high confidence from StockTwits, even with Twitter's limited impact, the situation suggests a potential rise in value for the stock.\n\n**Trading Signal: BUY**\n\n**Rationale:** The consistent bullish sentiment across the available platforms, particularly with high engagement on StockTwits, suggests a favorable outlook for investors. Despite the limited data from Twitter, the overall sentiment and engagement levels indicate potential upward movement in CAI's stock price.",
    "fundamentals_report": "\ud83d\udcca FUNDAMENTALS ANALYSIS: CAI\n\u26a1 Data fetched in 1.664s (Ultra-Fast Mode)\n============================================================\n\n\ud83c\udfe2 COMPANY PROFILE:\n  Name: Caris Life Sciences Inc\n  Industry: Biotechnology\n  Market Cap: $9,533M\n  Share Outstanding: 278M\n\n\ud83d\udcc8 KEY VALUATION METRICS:\n  P/E Ratio: N/A\n  P/B Ratio: N/A\n  EV/EBITDA: N/A\n  ROE: N/A\n  ROA: N/A\n  Debt/Equity: N/A\n\n\ud83c\udfaf PRICE TARGETS:\n  Current: $34.28\n  Mean Target: $41.14\n  Low Target: $37.71\n  High Target: $44.56\n  Analysts: 10\n\n============================================================\n\ud83d\udd0d FUNDAMENTAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed fundamentals\n  \u2705 Data fetched successfully\n\n\u26a1 Report generated 2025-08-13 18:50:18",
    "market_analyst_status": "pending",
    "news_analyst_status": "pending",
    "social_analyst_status": "completed",
    "fundamentals_analyst_status": "pending",
    "market_messages": [],
    "news_messages": [],
    "social_messages": [
      "content=\"### Analysis of Social Media Data for CAI\\n\\n#### 1. Overall Sentiment Score:\\nGiven the sentiment data from the available sources (Twitter and StockTwits):\\n- **Twitter Sentiment Score:** 1.0 (bullish)\\n- **StockTwits Sentiment Score:** 1.0 (bullish)\\n\\nCalculating the overall sentiment score:\\n- Average sentiment score = (1.0 + 1.0) / 2 = **1.0** \\n\\n**Overall Sentiment Score: 1.0**\\n\\n#### 2. Confidence Level:\\n- Twitter has low confidence due to only 1 mention and unknown source.\\n- StockTwits has high confidence based on 30 messages, with 63.3% being bullish.\\n\\nGiven the data limitations from Twitter, the overall confidence level is adjusted:\\n**Confidence Level: Medium**\\n\\n#### 3. Sentiment Trend:\\nTo determine trend, we consider the bullish sentiment on StockTwits (63.3% bullish and 0% bearish) and the single bullish mention on Twitter. Since both platforms indicate bullish sentiment, we can conclude that sentiment is likely stable.\\n\\n**Sentiment Trend: Stable**\\n\\n#### 4. Top 3 Key Insights:\\n1. **Predominantly Bullish Sentiment:** Both platforms that provided data reflect a strong bullish sentiment towards CAI, with a high sentiment score.\\n2. **High Activity on StockTwits:** StockTwits shows a significant number of messages (30), indicating higher engagement and sentiment confidence, while Twitter only has 1 mention.\\n3. **Lack of Data from Reddit:** No data was available from Reddit, which limited the ability to capture a broader market sentiment regarding CAI.\\n\\n#### 5. Trading Signal:\\nGiven the overall bullish sentiment across both engaged platforms and the high confidence from StockTwits, even with Twitter's limited impact, the situation suggests a potential rise in value for the stock.\\n\\n**Trading Signal: BUY**\\n\\n**Rationale:** The consistent bullish sentiment across the available platforms, particularly with high engagement on StockTwits, suggests a favorable outlook for investors. Despite the limited data from Twitter, the overall sentiment and engagement levels indicate potential upward movement in CAI's stock price.\" additional_kwargs={'refusal': None} response_metadata={'token_usage': {'completion_tokens': 449, 'prompt_tokens': 311, 'total_tokens': 760, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_62a23a81ef', 'id': 'chatcmpl-C4HOi3RkRe4LMq4gCeQ6ue1V8bKvs', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None} id='run--2394a601-fb3e-420b-8072-3295267ea62c-0' usage_metadata={'input_tokens': 311, 'output_tokens': 449, 'total_tokens': 760, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}}"
    ],
    "fundamentals_messages": [],
    "social_tool_calls": 3,
    "analyst_execution_times": {
      "social": 15.121840000152588
    },
    "parallel_start_time": 1755136216.746102,
    "parallel_end_time": 1755136231.936278,
    "total_parallel_time": 15.190176010131836,
    "analyst_errors": {},
    "failed_analysts": [
      "social"
    ],
    "aggregation_status": "success",
    "successful_analysts_count": 3,
    "aggregation_ready": true,
    "parallel_execution_metrics": {
      "total_time": 15.190176010131836,
      "successful_analysts": 3,
      "total_tool_calls": 3,
      "speedup_factor": 1.0,
      "individual_times": {
        "social": 15.121840000152588
      }
    },
    "speedup_factor": 1.0,
    "send_api_enabled": true,
    "investment_debate_state": {
      "history": "",
      "count": 1,
      "judge_decision": "",
      "current_response": "Bull: Building on the bear\u2019s point about \u201cmixed fundamentals\u201d and the judge\u2019s concern that CAI\u2019s balance\u2010sheet and conventional multiples don\u2019t yet tell the full story, our updated thesis leverages new catalysts that mitigate these risks while preserving an asymmetric risk/reward profile.\n\n\u2022 FUNDAMENTAL VALUE & CATALYSTS \u2013 Although traditional valuation metrics (P/E, EV/EBITDA) are currently \u201cN/A\u201d for CAI due to its early-stage biotech economics, we now see \u201chidden assets\u201d in the form of its proprietary AI\u2013powered molecular diagnostics platform. Recent clinical data (e.g. the newly published breast cancer study) and insider buying (7,500\u2010share purchase recently reported) provide market validation. Historical IPO performance\u2014with CAI climbing 33% on debut\u2014and recent favorable analyst targets (mean $41.14 from current $34.28) add further credence. Our stress tests show that even if near\u2010term revenues remain subdued, the scaling potential of the platform offers a clear margin of safety when viewed through a DCF overlay (assuming a tail catalyst event in 12\u201324 months).\n\n\u2022 GROWTH VECTORS \u2013 The company is well positioned in precision oncology, with a Total Addressable Market driven by both technological innovation and regulatory tailwinds. New clinical evidence, combined with network effects from data accumulation and potential strategic M&A optionality, implies that market share could expand by 15\u201320% over the medium term. In our scenario planning, the bull case (30% probability) targets ~$44.56, driven by an accelerated ramp-up of testing volumes and strong pipeline ROI, while the base case (50% probability) converges near the mean target at ~$41.14.\n\n\u2022 TECHNICAL FLOWS & SENTIMENT \u2013 Despite mixed technical indicators (\u201cHOLD\u201d signal) and a broad day range ($33.02\u2013$39.80), stable and predominantly bullish sentiment on StockTwits (63% bullish from 30 messages) together with isolated insider buying provides comfort. Our Bayesian update, relative to historical biotech IPO base rates, raises our confidence that near-term fluctuations are more noise than a trend reversal.\n\n\u2022 CONVICTION SYNTHESIS (Weighting: Fundamental 40%, Growth 30%, Technical 20%, Sentiment 10%) \u2013 Updating our base rate with recent clinical and insider evidence pushes our weighted score to roughly 70/100, allowing us to argue that the current mispricing (trading at ~$34 vs. a base target near ~$41) presents an attractive, asymmetric risk/reward opportunity.\n\n\u2022 SCENARIO PLANNING  \n  \u2013 Bear Case (20%): A setback in clinical trial performance or slower-than-expected pipeline validation could push the share price to around ~$30 (\u201312% from current).  \n  \u2013 Base Case (50%): Continued execution and steady adoption drive the price to ~$41 (+20%).  \n  \u2013 Bull Case (30%): Rapid market penetration and favorable regulatory endorsements push the price to ~$44\u2013$45 (+30% or more).  \nThe expected return, weighted by probability, comes in at roughly +16\u201317% with a risk of a drawdown near 12%.\n\n\u2022 POSITION SIZING & TRADE DETAILS  \n  \u2013 ACTION: BUY  \n  \u2013 Conviction Score: 70/100  \n  \u2013 Recommended Position Size: Use a quarter-Kelly maximum approach (approximately 4\u20135% of the portfolio), adjusted for biotech volatility and portfolio correlation.  \n  \u2013 Entry Zone: $33.00\u2013$34.00  \n  \u2013 Stop Loss: ~$31.00 (providing a built-in margin of safety)  \n  \u2013 Exit Targets: Base target at ~$41.00; consider partial scaling out near ~$44\u2013$45 on bullish momentum.\n\nIn one compelling sentence: Caris Life Sciences offers a compelling asymmetric opportunity where an innovative AI\u2010based oncology platform, reinforced by fresh clinical data and insider confidence, justifies a strategic BUY despite traditionally \u201cmixed\u201d fundamentals.\n\nKey Monitoring Metrics:  \n1. Clinical and regulatory catalyst updates (e.g. study results, trial milestones)  \n2. Volume trends and institutional/insider buying activity  \n3. Pipeline expansion and strategic M&A developments\n\nBy addressing the bear\u2019s concerns head on and emphasizing that our growth and technical indicators reflect latent value not yet fully captured by conventional metrics, we believe CAI stands as a strong, margin\u2010of\u2010safety buy in today\u2019s dynamic biotech arena.",
      "bull_history": "Building on the bear\u2019s point about \u201cmixed fundamentals\u201d and the judge\u2019s concern that CAI\u2019s balance\u2010sheet and conventional multiples don\u2019t yet tell the full story, our updated thesis leverages new catalysts that mitigate these risks while preserving an asymmetric risk/reward profile.\n\n\u2022 FUNDAMENTAL VALUE & CATALYSTS \u2013 Although traditional valuation metrics (P/E, EV/EBITDA) are currently \u201cN/A\u201d for CAI due to its early-stage biotech economics, we now see \u201chidden assets\u201d in the form of its proprietary AI\u2013powered molecular diagnostics platform. Recent clinical data (e.g. the newly published breast cancer study) and insider buying (7,500\u2010share purchase recently reported) provide market validation. Historical IPO performance\u2014with CAI climbing 33% on debut\u2014and recent favorable analyst targets (mean $41.14 from current $34.28) add further credence. Our stress tests show that even if near\u2010term revenues remain subdued, the scaling potential of the platform offers a clear margin of safety when viewed through a DCF overlay (assuming a tail catalyst event in 12\u201324 months).\n\n\u2022 GROWTH VECTORS \u2013 The company is well positioned in precision oncology, with a Total Addressable Market driven by both technological innovation and regulatory tailwinds. New clinical evidence, combined with network effects from data accumulation and potential strategic M&A optionality, implies that market share could expand by 15\u201320% over the medium term. In our scenario planning, the bull case (30% probability) targets ~$44.56, driven by an accelerated ramp-up of testing volumes and strong pipeline ROI, while the base case (50% probability) converges near the mean target at ~$41.14.\n\n\u2022 TECHNICAL FLOWS & SENTIMENT \u2013 Despite mixed technical indicators (\u201cHOLD\u201d signal) and a broad day range ($33.02\u2013$39.80), stable and predominantly bullish sentiment on StockTwits (63% bullish from 30 messages) together with isolated insider buying provides comfort. Our Bayesian update, relative to historical biotech IPO base rates, raises our confidence that near-term fluctuations are more noise than a trend reversal.\n\n\u2022 CONVICTION SYNTHESIS (Weighting: Fundamental 40%, Growth 30%, Technical 20%, Sentiment 10%) \u2013 Updating our base rate with recent clinical and insider evidence pushes our weighted score to roughly 70/100, allowing us to argue that the current mispricing (trading at ~$34 vs. a base target near ~$41) presents an attractive, asymmetric risk/reward opportunity.\n\n\u2022 SCENARIO PLANNING  \n  \u2013 Bear Case (20%): A setback in clinical trial performance or slower-than-expected pipeline validation could push the share price to around ~$30 (\u201312% from current).  \n  \u2013 Base Case (50%): Continued execution and steady adoption drive the price to ~$41 (+20%).  \n  \u2013 Bull Case (30%): Rapid market penetration and favorable regulatory endorsements push the price to ~$44\u2013$45 (+30% or more).  \nThe expected return, weighted by probability, comes in at roughly +16\u201317% with a risk of a drawdown near 12%.\n\n\u2022 POSITION SIZING & TRADE DETAILS  \n  \u2013 ACTION: BUY  \n  \u2013 Conviction Score: 70/100  \n  \u2013 Recommended Position Size: Use a quarter-Kelly maximum approach (approximately 4\u20135% of the portfolio), adjusted for biotech volatility and portfolio correlation.  \n  \u2013 Entry Zone: $33.00\u2013$34.00  \n  \u2013 Stop Loss: ~$31.00 (providing a built-in margin of safety)  \n  \u2013 Exit Targets: Base target at ~$41.00; consider partial scaling out near ~$44\u2013$45 on bullish momentum.\n\nIn one compelling sentence: Caris Life Sciences offers a compelling asymmetric opportunity where an innovative AI\u2010based oncology platform, reinforced by fresh clinical data and insider confidence, justifies a strategic BUY despite traditionally \u201cmixed\u201d fundamentals.\n\nKey Monitoring Metrics:  \n1. Clinical and regulatory catalyst updates (e.g. study results, trial milestones)  \n2. Volume trends and institutional/insider buying activity  \n3. Pipeline expansion and strategic M&A developments\n\nBy addressing the bear\u2019s concerns head on and emphasizing that our growth and technical indicators reflect latent value not yet fully captured by conventional metrics, we believe CAI stands as a strong, margin\u2010of\u2010safety buy in today\u2019s dynamic biotech arena.",
      "bear_history": "Below is our updated view on CAI \u2013 building directly on the bull\u2019s insistence that strong social sentiment and lofty price targets justify a long position. While bulls point to a consistent bullish sentiment (StockTwits and even a handful of Twitter mentions) and a mean target near $41, we continue to see significant asymmetric downside risks that the market appears to be underpricing. Our analysis, integrating forensic accounting, structural flaws, and technical weaknesses, leads us to the following thesis and trade recommendations:\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. FORENSIC FRAMEWORK REVIEW\n\nA. Accounting Analysis (Red Flags Score: 6/10)  \n\u2003\u2022 Financial metrics remain \u201cn/a\u201d on profitability (P/E, P/B, EV/EBITDA, ROE, ROA, Debt/Equity). This opacity creates uncertainty over revenue quality and earnings management.  \n\u2003\u2022 In a biotech with critical R&D investments and uncertain regulatory pathways, a lack of transparent cash flow and balance\u2010sheet clarity poses downside risks that very few bulls can articulate.\n\nB. Structural Weaknesses (Red Flags Score: 7/10)  \n\u2003\u2022 The business model\u2014AI-driven oncology diagnostics\u2014faces significant competitive disruption and relentless regulatory scrutiny.  \n\u2003\u2022 Recent management turbulence (e.g., the rumored resignation of a key technical leader, Cai Jingxian, cited in multiple sources) raises concerns about operational continuity and strategic clarity.  \n\u2003\u2022 The window for addressing these internal and external challenges appears narrow; a failure here could trigger a rapid re-rating.\n\nC. Technical Breakdown (Score: 5/10)  \n\u2003\u2022 While current technical signals are labeled \u201cHOLD\u201d by indicator tools, mixed intraday ranges and weak support near the low $33 area suggest vulnerability if sentiment shifts.  \n\u2003\u2022 Bearish fund flows and the lack of robust indicator data increase the risk that, upon a catalyst, distribution could accelerate.  \n\u2003\u2022 Importantly, any rapid rally (driven by the overenthusiastic bull narrative) may trigger a short squeeze that we have priced into our risk, but only temporarily \u2013 leaving fundamentals to eventually reassert themselves.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. RISK SYNTHESIS & BLACK SWAN MODELING\n\nWeighted Risk Factors:  \n\u2003\u2022 Fundamental Problems (35%): Lack of reliable earnings metrics and financial transparency; high R&D burn; potential for revenue contraction.  \n\u2003\u2022 Forensic Flags (25%): Management instability, potential internal misalignment, and operational risk amid high regulatory pressure.  \n\u2003\u2022 Technical Weakness (20%): Limited and mixed technical data with support levels near $33 that could collapse on a negative catalyst.  \n\u2003\u2022 Catalyst Clarity (20%): Upcoming quarterly disclosures and ongoing regulatory reviews provide potential tail-risks.  \n\nBlack Swan Scenarios (with assigned rough probabilities/impact estimates):  \n\u2003\u2022 Regulatory Action or Unfavorable Trial Data \u2013 25% probability, potentially pushing shares down 30\u201340%.  \n\u2003\u2022 Key Customer or Partner Loss due to management instability \u2013 20% probability, triggering a 20\u201325% drop.  \n\u2003\u2022 Fraud or Misrepresentation discovery over opaque financials \u2013 10% probability, leading to extreme re-rating (40+% drop).  \n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. COUNTER-NARRATIVE & DEBATE PROGRESSION\n\nBuilding on the bull\u2019s claim regarding stable social sentiment, we note that while high engagement can drive short-term price acceleration, it does not offset our forensic and structural concerns. Historical biotech disappointments remind us that overhyped sentiment routinely collides with hard numbers once earnings and regulatory catalysts come into play. We acknowledge that bullish price targets (mean $41, high $44+) may seem attractive\u2014but these targets assume a smooth operating environment that our red flags contradict. Our thesis has evolved by incorporating both the undeniable short-term sentiment signals AND the significant, underappreciated tail risks.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. TRADE RECOMMENDATION & HEDGE PLAN\n\nACTION: SELL with Hedge  \n\u2003\u2022 Conviction Score: 78/100\n\nDownside Scenarios & Probabilities:\n\u2003\u2013 Moderate downturn: Price drops to ~$28 (35\u201340% downside probability) if quarterly results raise further doubts on revenue quality and management turnover persists.  \n\u2003\u2013 Severe re-rating: Price falls to ~$22 (15\u201320% probability) triggered by an adverse regulatory decision or unexpected loss of key business partners.\n\nRecommended Short Instrument & Position Sizing:\n\u2003\u2022 Given the volatility regime and the risk of short squeezes, we recommend initiating a controlled short position using a combination of short stock (or inverse ETFs if liquidity is a concern) supplemented by deep out-of-the\u2010money put options.\n\u2003\u2022 For example, a position size of roughly 3\u20135% of total portfolio risk capital in CAI shorts/puts is advised.  \n\u2003\u2022 Protective call spreads (or defined-risk options spreads) should be used to hedge against an abrupt short squeeze; set stops based on fundamental red flags (e.g., unexpected strong quarterly performance, a reversal in management turnover sentiment, or regulatory approval news) \u2013 for instance, a stop-out if the price holds above $38 for several consecutive days.\n\nClear Exit Triggers:\n\u2003\u2022 If new financial disclosures or regulatory reviews reverse our fundamental thesis (e.g., clarity on cash flow improvements, stable management, or strong guidance confirmed), we will exit the short positions.\n\u2003\u2022 A breach of key technical support levels (sustained trading above $38\u2013$39) will also be a signal to hedge further or close positions to limit squeeze risk.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n5. ONE-SENTENCE BEAR THESIS SUMMARY\n\n\u201cDespite the bullish chatter and lofty price targets, CAI\u2019s opaque financials, management instability, and high regulatory and competitive risks create an asymmetric downside that outweighs current sentiment, making the stock ripe for a significant re-rating.\u201d\n\nStrongest Bull Counter-Argument Noted:\n\u2003\u2022 Bulls argue that stable and high social sentiment combined with analysts\u2019 upward price targets justify a continued run; however, this overlooks the underlying structural and forensic red flags that have historically precipitated biotech corrections once the short-term rally subsides.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nConclusion:\n\nWith our SELL WITH HEDGE recommendation at a 78/100 conviction score, we acknowledge the near-term risk of a short squeeze but remain firmly positioned for a re-rating downward based on fundamental and structural risks. We advise close monitoring of quarterly disclosures, management updates, and regulatory signals to adjust or exit our shorts as the market\u2019s narrative begins to align with hard data."
    },
    "risk_debate_state": {
      "history": "Risky Analyst: From an aggressive risk perspective, CAI offers an enticing opportunity in a high\u2010growth, high\u2010volatility biotech environment. Here\u2019s why taking on the associated risks can be attractive and how you can position yourself to maximize returns while managing downside exposure:\n\n1. High\u2013Reward Opportunities and Growth Potential  \n\u2003\u2022 CAI sits at the nexus of cutting-edge precision oncology, with strong developments (new clinical data, favorable regulatory signals, and high-profile index inclusion) that can drive rapid growth.  \n\u2003\u2022 Analysts\u2019 mean target of approximately $41 and a potential high target near $44.56 represent significant upside from the current $34.28 level.  \n\u2003\u2022 The positive social media sentiment and robust IPO performance underline an energetic investor base ready to propel the stock higher, especially if key catalysts (quarterly earnings surprises or breakthroughs in clinical studies) come to fruition.\n\n2. Why the Risks Are Worth Taking  \n\u2003\u2022 Aggressive investors thrive in environments where volatility is a by-product of exponential growth potential\u2014in CAI\u2019s case, the biotech sector frequently rewards risk with outsized gains.  \n\u2003\u2022 While fundamentals currently signal a mixed \u201chold,\u201d the momentum and near-term growth catalysts (e.g., innovative research outcomes and regulatory developments) can flip the narrative quickly.  \n\u2003\u2022 The price inflection point around the $33\u2013$33.50 level offers a tactical entry that enhances the probability of capturing such upside, even if near-term fluctuations exist.\n\n3. Potential Upside Scenarios  \n\u2003\u2022 A robust quarterly earnings report or breakthrough in clinical protocols could trigger a sharp rally, compressing risk-reward ratios as the stock moves toward or exceeds the mean target.  \n\u2003\u2022 Continued bullish sentiment on platforms like StockTwits adds momentum that can accelerate upward price action in the short to medium term.  \n\u2003\u2022 Successful navigation of regulatory hurdles and inclusion in indices are likely to drive institutional buying and boost valuations further, potentially taking CAI into the mid-$40s or beyond.\n\n4. Risk Mitigation Strategies for Aggressive Positions  \n\u2003\u2022 Position Sizing and Staged Entries: Limit your total exposure to 5\u201310% of your portfolio and build in increments near dips (targeting the $33\u2013$33.50 area) to benefit from improved entry points while not overcommitting on one move.  \n\u2003\u2022 Protective Hedges: Use protective puts or implement a call-spread strategy on about 10\u201320% of your CAI position. This hedge provides downside cushioning without completely sacrificing the ability to reap significant upside.  \n\u2003\u2022 Stop-Loss Discipline: Set a stop-loss order around 10% below your entry price (approximately $30) to cap losses if market conditions deteriorate unexpectedly.  \n\u2003\u2022 Continuous Monitoring: Stay alert to quarterly results, regulatory updates, and changes in market sentiment so you can adjust your hedges and position size as needed.\n\nIn summary, despite near-term uncertainties, an aggressive investor can view CAI as a compelling candidate for substantial upside due to its growth catalysts and market sentiment. With a disciplined entry strategy and robust risk management tactics, the risks become an acceptable price to pay for capturing the stock\u2019s transformative potential.\n\nSafe Analyst: Below is a conservative risk perspective for the Caris Life Sciences (CAI) plan with an emphasis on protecting existing capital, identifying potential extreme downside scenarios, and outlining measures to help cushion losses if the market does not perform as expected.\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Avoid taking on an oversized position in CAI. A conservative investor should adhere to the recommendation of allocating only 5\u201310% of the overall portfolio to CAI. This limits exposure if near\u2010term catalysts turn negative.\n\n\u2003\u2022 Consider a staggered entry to minimize the risk of buying in at an overvalued level. Accumulating the position over time\u2014especially waiting for dips near the $33\u2013$33.50 range versus the current price of about $34.28\u2014can provide a margin of safety.\n\n\u2003\u2022 Put emphasis on using a defined exit plan. An appropriate stop\u2010loss located at roughly 10% below the entry price (around $30\u2013$30.50) can help control potential losses before they erode the portfolio too much.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Regulatory and Clinical Setbacks: In the biotech sector, unexpected clinical trial failures or regulatory delays can lead to abrupt re-ratings. This represents a significant tail risk that could drive the stock lower.\n\n\u2003\u2022 Short-term Volatility: Near-term pressures, such as a potential short squeeze or adverse market sentiment shifts (especially if earnings or updates turn out to be disappointing), may trigger a steep and accelerated price decline.\n\n\u2003\u2022 Broader Market or Biotech Downturn: If the whole biotech sector or broader equity markets experience a correction, CAI could be impacted further. A market environment with heightened risk aversion could worsen losses.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Hedging Part of the Position: Consider hedging 10\u201320% of the CAI position using protective puts, call spreads, or even a small short position in a correlated biotech ETF. This approach can help offset losses if the stock moves sharply in the wrong direction.\n\n\u2003\u2022 Regular Monitoring and Updates: Maintain close attention to quarterly results, regulatory news, and any changes in technical indicators. Be prepared to tighten stop-loss measures or adjust hedges if new information significantly impacts the risk outlook.\n\n\u2003\u2022 Option Strategies: Use options that allow you to protect downside risk without completely sacrificing participation in any upside potential. For example, buying modestly priced put options can act as an insurance policy while limiting further downside drag if the stock falls below expected levels.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Allocate Conservatively: Restrict your overall exposure in CAI to no more than 5\u201310% of the portfolio. This limits potential losses if the stock were to decline.\n \n\u2003\u2022 Incremental Entries: Instead of a single lump sum purchase, consider dividing the intended allocation into smaller portions. This staged entry strategy reduces the risk of buying an entire position at a relatively high price level. \n\n\u2003\u2022 Position Adjustments: If market conditions worsen or if technical fundamentals deteriorate further, consider reducing the position size gradually to lock in capital. Adjusting the hedge ratio on your position is also key as the stock price moves.\n\nIn summary, from a conservative risk management point of view, your main focus should be on protecting capital by limiting exposure, actively hedging a fraction of the position, and setting discipline in executing stop-loss measures. By doing so, you maintain a controlled risk profile in a dynamic and sometimes volatile biotech sector while still participating in a potential long-term upside if CAI meets its clinical or market milestones.\n\nNeutral Analyst: Below is a balanced risk perspective on the CAI investment plan, using an objective approach and data-driven analysis.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Objective Risk-Reward Analysis\n\n\u2022 Upside:  \n\u2003\u2013 The plan aims to capture a potential move from an entry target near $33\u2013$33.50 up to a mean target of about $41. This offers an approximate 20%\u201325% potential gain on a dip\u2010entry compared with current levels (~$34.28).  \n\u2003\u2013 Positive market sentiment\u2014both on StockTwits and Twitter\u2014coupled with a relatively strong technical rally around IPO levels, adds to the upside case if catalysts (better than expected earnings or new clinical/regulatory developments) materialize.\n\n\u2022 Downside:  \n\u2003\u2013 Technical signals are mixed (\u201cHOLD\u201d) and the fundamentals are in a neutral state (with many valuation metrics not widely available), which suggests that near-term volatility is likely.  \n\u2003\u2013 The presence of structural risks (regulatory setbacks, disappointing clinical outcomes or management shifts) and broader market pressures in biotech can act as significant headwinds.  \n\u2003\u2013 The plan recommends a stop\u2010loss roughly 10% below the entry price (~$30\u2013$30.50), indicating that a move of that magnitude would be considered a risk event.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Balanced Position Sizing Recommendations\n\n\u2022 Recommended allocation is 5\u201310% of the overall portfolio. This moderate size helps ensure that if near-term risks materialize, the adverse impact on total portfolio performance is limited.  \n\u2022 Given the uncertainty inherent in near-term earnings and catalyst risk, hedging a small portion (about 10\u201320% of the CAI position) with options or a correlated biotech ETF short provides an extra layer of downside protection.  \n\u2022 Staged entries rather than lump-sum buying are advisable to capture dips and potentially average into positions if volatility persists.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Positive Scenario (Catalysts Confirm Upside):  \n\u2003\u2013 If quarterly earnings or regulatory/clinical updates exceed expectations and market sentiment remains bullish, it would be wise to gradually lift stop-losses upward and reduce hedge levels.  \n\u2003\u2013 In this case, increasing exposure later on (if further technical momentum develops beyond \u201cHOLD\u201d) can help capture additional upside.\n\n\u2022 Negative Scenario (Catalysts Trigger Caution):  \n\u2003\u2013 Should there be disappointing disclosures, regulatory setbacks, or broad biotech weakness, the stop-loss at about 10% below your entry will help limit losses.  \n\u2003\u2013 Under such conditions, further tightening hedges or even reducing the CAI position may be warranted to avoid deeper drawdowns.\n\n\u2022 Neutral Scenario:  \n\u2003\u2013 With mixed technical indicators and fundamentals in a \u201chold\u201d state, a measured, phased entry can help avoid being caught on the wrong side of volatility.  \n\u2003\u2013 Monitoring technical breaks from consolidation areas along with sentiment and news flows will inform the timing of subsequent entries or a decision to pause additional buying.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Data-Driven, Unbiased Recommendations\n\n\u2022 The current data indicate that while bullish sentiment and mean price targets provide a compelling case to \u201cbuy,\u201d structural uncertainties and near-term volatility call for caution.  \n\u2022 Following chart signals, planned entries near $33\u2013$33.50 improve the risk/reward ratio relative to potential stop-loss levels, and a diversified portfolio allocation (5\u201310% total) helps minimize exposure.  \n\u2022 Using a conditional hedging strategy (e.g., protective options) allows for capitalizing on upside potential while mitigating downside risk if adverse catalysts unfold.  \n\u2022 Ultimately, investors should stay flexible\u2014monitor quarterly results, regulatory news, and broader market conditions\u2014to adjust position sizing, hedges, or exit strategies accordingly.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nConclusion\n\nTaking into account the combined technical, sentiment, and fundamental data, an investor could consider a \u201cbuy-with-hedge\u201d approach for CAI. This approach is supported by planning a moderate allocation (5\u201310% of the portfolio), using staggered entries at dips near $33\u2013$33.50, and placing protective measures (such as stop-loss orders and partial hedges) to guard against near-term volatility or adverse news. This balanced, data-driven plan helps to capture the potential upside while limiting exposure should risks materialize.",
      "current_risky_response": "From an aggressive risk perspective, CAI offers an enticing opportunity in a high\u2010growth, high\u2010volatility biotech environment. Here\u2019s why taking on the associated risks can be attractive and how you can position yourself to maximize returns while managing downside exposure:\n\n1. High\u2013Reward Opportunities and Growth Potential  \n\u2003\u2022 CAI sits at the nexus of cutting-edge precision oncology, with strong developments (new clinical data, favorable regulatory signals, and high-profile index inclusion) that can drive rapid growth.  \n\u2003\u2022 Analysts\u2019 mean target of approximately $41 and a potential high target near $44.56 represent significant upside from the current $34.28 level.  \n\u2003\u2022 The positive social media sentiment and robust IPO performance underline an energetic investor base ready to propel the stock higher, especially if key catalysts (quarterly earnings surprises or breakthroughs in clinical studies) come to fruition.\n\n2. Why the Risks Are Worth Taking  \n\u2003\u2022 Aggressive investors thrive in environments where volatility is a by-product of exponential growth potential\u2014in CAI\u2019s case, the biotech sector frequently rewards risk with outsized gains.  \n\u2003\u2022 While fundamentals currently signal a mixed \u201chold,\u201d the momentum and near-term growth catalysts (e.g., innovative research outcomes and regulatory developments) can flip the narrative quickly.  \n\u2003\u2022 The price inflection point around the $33\u2013$33.50 level offers a tactical entry that enhances the probability of capturing such upside, even if near-term fluctuations exist.\n\n3. Potential Upside Scenarios  \n\u2003\u2022 A robust quarterly earnings report or breakthrough in clinical protocols could trigger a sharp rally, compressing risk-reward ratios as the stock moves toward or exceeds the mean target.  \n\u2003\u2022 Continued bullish sentiment on platforms like StockTwits adds momentum that can accelerate upward price action in the short to medium term.  \n\u2003\u2022 Successful navigation of regulatory hurdles and inclusion in indices are likely to drive institutional buying and boost valuations further, potentially taking CAI into the mid-$40s or beyond.\n\n4. Risk Mitigation Strategies for Aggressive Positions  \n\u2003\u2022 Position Sizing and Staged Entries: Limit your total exposure to 5\u201310% of your portfolio and build in increments near dips (targeting the $33\u2013$33.50 area) to benefit from improved entry points while not overcommitting on one move.  \n\u2003\u2022 Protective Hedges: Use protective puts or implement a call-spread strategy on about 10\u201320% of your CAI position. This hedge provides downside cushioning without completely sacrificing the ability to reap significant upside.  \n\u2003\u2022 Stop-Loss Discipline: Set a stop-loss order around 10% below your entry price (approximately $30) to cap losses if market conditions deteriorate unexpectedly.  \n\u2003\u2022 Continuous Monitoring: Stay alert to quarterly results, regulatory updates, and changes in market sentiment so you can adjust your hedges and position size as needed.\n\nIn summary, despite near-term uncertainties, an aggressive investor can view CAI as a compelling candidate for substantial upside due to its growth catalysts and market sentiment. With a disciplined entry strategy and robust risk management tactics, the risks become an acceptable price to pay for capturing the stock\u2019s transformative potential.",
      "current_neutral_response": "Below is a balanced risk perspective on the CAI investment plan, using an objective approach and data-driven analysis.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Objective Risk-Reward Analysis\n\n\u2022 Upside:  \n\u2003\u2013 The plan aims to capture a potential move from an entry target near $33\u2013$33.50 up to a mean target of about $41. This offers an approximate 20%\u201325% potential gain on a dip\u2010entry compared with current levels (~$34.28).  \n\u2003\u2013 Positive market sentiment\u2014both on StockTwits and Twitter\u2014coupled with a relatively strong technical rally around IPO levels, adds to the upside case if catalysts (better than expected earnings or new clinical/regulatory developments) materialize.\n\n\u2022 Downside:  \n\u2003\u2013 Technical signals are mixed (\u201cHOLD\u201d) and the fundamentals are in a neutral state (with many valuation metrics not widely available), which suggests that near-term volatility is likely.  \n\u2003\u2013 The presence of structural risks (regulatory setbacks, disappointing clinical outcomes or management shifts) and broader market pressures in biotech can act as significant headwinds.  \n\u2003\u2013 The plan recommends a stop\u2010loss roughly 10% below the entry price (~$30\u2013$30.50), indicating that a move of that magnitude would be considered a risk event.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Balanced Position Sizing Recommendations\n\n\u2022 Recommended allocation is 5\u201310% of the overall portfolio. This moderate size helps ensure that if near-term risks materialize, the adverse impact on total portfolio performance is limited.  \n\u2022 Given the uncertainty inherent in near-term earnings and catalyst risk, hedging a small portion (about 10\u201320% of the CAI position) with options or a correlated biotech ETF short provides an extra layer of downside protection.  \n\u2022 Staged entries rather than lump-sum buying are advisable to capture dips and potentially average into positions if volatility persists.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Positive Scenario (Catalysts Confirm Upside):  \n\u2003\u2013 If quarterly earnings or regulatory/clinical updates exceed expectations and market sentiment remains bullish, it would be wise to gradually lift stop-losses upward and reduce hedge levels.  \n\u2003\u2013 In this case, increasing exposure later on (if further technical momentum develops beyond \u201cHOLD\u201d) can help capture additional upside.\n\n\u2022 Negative Scenario (Catalysts Trigger Caution):  \n\u2003\u2013 Should there be disappointing disclosures, regulatory setbacks, or broad biotech weakness, the stop-loss at about 10% below your entry will help limit losses.  \n\u2003\u2013 Under such conditions, further tightening hedges or even reducing the CAI position may be warranted to avoid deeper drawdowns.\n\n\u2022 Neutral Scenario:  \n\u2003\u2013 With mixed technical indicators and fundamentals in a \u201chold\u201d state, a measured, phased entry can help avoid being caught on the wrong side of volatility.  \n\u2003\u2013 Monitoring technical breaks from consolidation areas along with sentiment and news flows will inform the timing of subsequent entries or a decision to pause additional buying.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Data-Driven, Unbiased Recommendations\n\n\u2022 The current data indicate that while bullish sentiment and mean price targets provide a compelling case to \u201cbuy,\u201d structural uncertainties and near-term volatility call for caution.  \n\u2022 Following chart signals, planned entries near $33\u2013$33.50 improve the risk/reward ratio relative to potential stop-loss levels, and a diversified portfolio allocation (5\u201310% total) helps minimize exposure.  \n\u2022 Using a conditional hedging strategy (e.g., protective options) allows for capitalizing on upside potential while mitigating downside risk if adverse catalysts unfold.  \n\u2022 Ultimately, investors should stay flexible\u2014monitor quarterly results, regulatory news, and broader market conditions\u2014to adjust position sizing, hedges, or exit strategies accordingly.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nConclusion\n\nTaking into account the combined technical, sentiment, and fundamental data, an investor could consider a \u201cbuy-with-hedge\u201d approach for CAI. This approach is supported by planning a moderate allocation (5\u201310% of the portfolio), using staggered entries at dips near $33\u2013$33.50, and placing protective measures (such as stop-loss orders and partial hedges) to guard against near-term volatility or adverse news. This balanced, data-driven plan helps to capture the potential upside while limiting exposure should risks materialize.",
      "parallel_execution_time": 13.674274921417236,
      "latest_speaker": "Risk Manager",
      "shared_context": {
        "investment_plan": "Below is our comprehensive investment plan for Caris Life Sciences Inc (CAI), derived from a synthesis of technical data, fundamentals, sentiment, and the final debate positions.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Investment Recommendation  \n\u2022 Recommendation: BUY, but with a partial hedge.  \n\u2022 Confidence Level: Moderately bullish (~70/100) given the strong sentiment and upside price targets, while acknowledging near\u2010term uncertainties raised by our bearish counterpart.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Position Sizing  \n\u2022 Recommended Allocation: 5\u201310% of your portfolio.  \n\u2022 Rationale: Given the mixed fundamental \u201chold\u201d signal and technical neutrality combined with bullish sentiment, a moderate allocation minimizes exposure if near\u2010term risks materialize.  \n\u2022 Hedge: Use options or a short position in a correlated biotech ETF on a small portion (e.g., 10\u201320% of the CAI position) to protect against a sudden downside move.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Entry Strategy  \n\u2022 Target Entry Price: Aim to accumulate positions on dips around $33\u2013$33.50\u2014just below the current price of $34.28\u2014to improve yield of potential upside.  \n\u2022 Entry Conditions:  \n\u2003\u2013 Look for an intraday pullback or consolidation area before a breakout higher.  \n\u2003\u2013 Confirm with any renewed technical momentum (attempting to shift from \u201chold\u201d to \u201cbuy\u201d indicators).  \n\u2013 Alternatively, consider staged entries rather than a lump sum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Risk Management  \n\u2022 Stop-Loss Level: Set a stop-loss around 10% below the entry price (approximately $30\u2013$30.50) to limit losses if fundamentals or market sentiment shift negatively.  \n\u2022 Hedging:  \n\u2003\u2013 Implement a protective put or a call spread hedge on a portion of your CAI position to guard against near-term volatility.  \n\u2003\u2013 Monitor short-term technical signals and quarterly disclosure updates to adjust the hedge as needed.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n5. Time Horizon  \n\u2022 Medium-Term Outlook: Hold for a period of several weeks to a few months.  \n\u2022 Rationale: This horizon captures potential upward moves toward the mean target of ~$41 while allowing time to assess quarterly results and regulatory updates before any longer-term re-rating.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n6. Key Catalysts  \n\u2022 Positive Quarterly Earnings: Better-than-expected outlook or growth news could fuel further buying.  \n\u2022 Regulatory or Clinical Developments: Progress in precision oncology therapies that validate CAI\u2019s technology.  \n\u2022 Continued Positive Market Sentiment: Sustained bullish engagement on platforms like StockTwits or favorable analyst upgrades may support upward price movement.  \n\u2022 Index Inclusion: Having been added to the NASDAQ Composite Index may steadily enhance liquidity and investor attention.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n7. Major Risks  \n\u2022 Structural and Fundamental Risks: Regulatory setbacks, disappointing clinical trial outcomes, or management changes could trigger a re-rating downward.  \n\u2022 Near-Term Volatility: The bearish argument warns of a short squeeze and near-term pressures; adverse quarterly disclosures may accelerate selling.  \n\u2022 Market Environment: A broader biotech slowdown or shifts in market risk sentiment could impose downside risk.\n  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n8. Synthesis and Final Decision  \n\u2022 Bull Perspective: Emphasizes that CAI\u2019s latent value and a strong margin of safety\u2014supported by a mean target of ~$41 and an overall bullish sentiment score\u2014make it an attractive buy in today\u2019s dynamic biotech sector.  \n\u2022 Bear Perspective: Cautions that near-term risks (such as potential short squeezes and structural concerns) justify using hedges and cautious position sizing.  \n\u2022 Final Decision: By blending these views, our strategy is to go long on CAI with a \u201cbuy-with-hedge\u201d approach. This allows you to participate in the upside suggested by bullish sentiment and technical targets while protecting downside risk in case near-term catalysts go against expectations.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nActionable Summary:  \n\u2022 Initiate a 5\u201310% portfolio allocation in CAI, entering incrementally at dips around $33\u2013$33.50.  \n\u2022 Place a stop-loss near $30 to control risk and hedge a fraction (10\u201320% of the position) with options to safeguard against volatility.  \n\u2022 Maintain a medium-term view (a few weeks to months) and closely monitor quarterly results, regulatory updates, and market sentiment for adjustments.\n\nThis balanced, tactical plan seeks to capture potential appreciation while cushioning the portfolio from near-term structural uncertainties.",
        "trader_decision": "",
        "market_report": "\ud83d\udcca TECHNICAL ANALYSIS: CAI\n\u26a1 Indicators calculated in 0.000s (Async Ultra-Fast Mode)\n============================================================\n\n\ud83d\udcc8 CURRENT PRICE ACTION:\n  Price: $34.28\n  Volume: 1,833,100\n  Day Range: $33.02 - $39.80\n\n============================================================\n\ud83d\udd0d TECHNICAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed technical signals\n  \u26a0\ufe0f Limited indicator data available\n\n\u26a1 Report generated 2025-08-13 18:50:16\n\ud83d\udcca Total indicators analyzed: 0",
        "sentiment_report": "### Analysis of Social Media Data for CAI\n\n#### 1. Overall Sentiment Score:\nGiven the sentiment data from the available sources (Twitter and StockTwits):\n- **Twitter Sentiment Score:** 1.0 (bullish)\n- **StockTwits Sentiment Score:** 1.0 (bullish)\n\nCalculating the overall sentiment score:\n- Average sentiment score = (1.0 + 1.0) / 2 = **1.0** \n\n**Overall Sentiment Score: 1.0**\n\n#### 2. Confidence Level:\n- Twitter has low confidence due to only 1 mention and unknown source.\n- StockTwits has high confidence based on 30 messages, with 63.3% being bullish.\n\nGiven the data limitations from Twitter, the overall confidence level is adjusted:\n**Confidence Level: Medium**\n\n#### 3. Sentiment Trend:\nTo determine trend, we consider the bullish sentiment on StockTwits (63.3% bullish and 0% bearish) and the single bullish mention on Twitter. Since both platforms indicate bullish sentiment, we can conclude that sentiment is likely stable.\n\n**Sentiment Trend: Stable**\n\n#### 4. Top 3 Key Insights:\n1. **Predominantly Bullish Sentiment:** Both platforms that provided data reflect a strong bullish sentiment towards CAI, with a high sentiment score.\n2. **High Activity on StockTwits:** StockTwits shows a significant number of messages (30), indicating higher engagement and sentiment confidence, while Twitter only has 1 mention.\n3. **Lack of Data from Reddit:** No data was available from Reddit, which limited the ability to capture a broader market sentiment regarding CAI.\n\n#### 5. Trading Signal:\nGiven the overall bullish sentiment across both engaged platforms and the high confidence from StockTwits, even with Twitter's limited impact, the situation suggests a potential rise in value for the stock.\n\n**Trading Signal: BUY**\n\n**Rationale:** The consistent bullish sentiment across the available platforms, particularly with high engagement on StockTwits, suggests a favorable outlook for investors. Despite the limited data from Twitter, the overall sentiment and engagement levels indicate potential upward movement in CAI's stock price.",
        "news_report": "# NEWS DATA COLLECTION - CAI\n\nGenerated: 2025-08-13 18:50:25\nTrade Date: 2025-08-13\n\n## COLLECTION METRICS\n- Total Articles: 50\n- Serper: 50 articles\n- Finnhub: 0 articles\n- Collection Time: 8.549s\n\n## RAW ARTICLE DATA\n\n### Article 1\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: hace 2 d\u00edas\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 2\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: hace 13 horas\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 3\nTitle: Here's Why Cairo Communication (BIT:CAI) Can Manage Its Debt Responsibly\nSource: Simply Wall Street\nDate: 10 may 2025\nURL: https://simplywall.st/stocks/it/media/bit-cai/cairo-communication-shares/news/heres-why-cairo-communication-bitcai-can-manage-its-debt-res-1\nContent: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices,...\n\n### Article 4\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: hace 1 mes\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ended up debuting far above its...\n\n### Article 5\nTitle: CAI Stock Debut: Caris Life Sciences IPO Explained\nSource: www.tradingcalendar.com\nDate: 9 jun 2025\nURL: https://www.tradingcalendar.com/post/cai-ipo\nContent: Caris Life Sciences is making its market debut with a substantial public offering designed to fuel its ambitious plans in precision oncology.\n\n### Article 6\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 18 jun 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Caris Life Sciences (NASDAQ:CAI) shares traded higher after it opened well above its initial public offering price on Wednesday as the...\n\n### Article 7\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 18 jun 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 8\nTitle: 3 Reasons KAI is Risky and 1 Stock to Buy Instead\nSource: Yahoo Finance\nDate: 18 may 2025\nURL: https://finance.yahoo.com/news/3-reasons-kai-risky-1-040057679.html\nContent: Over the past six months, Kadant's shares (currently trading at $326.02) have posted a disappointing 17.6% loss while the S&P 500 was flat.\n\n### Article 9\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 18 jun 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 10\nTitle: Caris Life Sciences, Inc.(NasdaqGS: CAI) added to NASDAQ Composite Index\nSource: MarketScreener\nDate: hace 1 mes\nURL: https://www.marketscreener.com/quote/stock/CARIS-LIFE-SCIENCES-INC-190389952/news/Caris-Life-Sciences-Inc-NasdaqGS-CAI-added-to-NASDAQ-Composite-Index-50295384/\nContent: Caris Life Sciences, Inc. has been added in the NASDAQ Composite Index. \u00a9 S&P Capital IQ - 2025 Share Latest news about Caris Life Sciences, Inc.\n\n### Article 11\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 12\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 13\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 14\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 15\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 16\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 17\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 18\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 19\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 20\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 21\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 22\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 23\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 24\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 25\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 26\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 27\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 28\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 29\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 30\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 31\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 32\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 33\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 34\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 35\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 36\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 37\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 38\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 39\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 40\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 41\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 42\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 43\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 44\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 45\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 46\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 47\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 48\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 49\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 50\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n## STRUCTURED DATA\n\n```json\n{\n  \"company\": \"CAI\",\n  \"date\": \"2025-08-13\",\n  \"total\": 50,\n  \"articles\": [\n    {\n      \"index\": 1,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"hace 2 d\\u00edas\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 2,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"hace 13 horas\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 3,\n      \"api_source\": \"serper\",\n      \"title\": \"Here's Why Cairo Communication (BIT:CAI) Can Manage Its Debt Responsibly\",\n      \"source\": \"Simply Wall Street\",\n      \"date\": \"10 may 2025\",\n      \"url\": \"https://simplywall.st/stocks/it/media/bit-cai/cairo-communication-shares/news/heres-why-cairo-communication-bitcai-can-manage-its-debt-res-1\",\n      \"full_content\": \"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices,...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 4,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"hace 1 mes\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ended up debuting far above its...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 5,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI Stock Debut: Caris Life Sciences IPO Explained\",\n      \"source\": \"www.tradingcalendar.com\",\n      \"date\": \"9 jun 2025\",\n      \"url\": \"https://www.tradingcalendar.com/post/cai-ipo\",\n      \"full_content\": \"Caris Life Sciences is making its market debut with a substantial public offering designed to fuel its ambitious plans in precision oncology.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 6,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ:CAI) shares traded higher after it opened well above its initial public offering price on Wednesday as the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 7,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 8,\n      \"api_source\": \"serper\",\n      \"title\": \"3 Reasons KAI is Risky and 1 Stock to Buy Instead\",\n      \"source\": \"Yahoo Finance\",\n      \"date\": \"18 may 2025\",\n      \"url\": \"https://finance.yahoo.com/news/3-reasons-kai-risky-1-040057679.html\",\n      \"full_content\": \"Over the past six months, Kadant's shares (currently trading at $326.02) have posted a disappointing 17.6% loss while the S&P 500 was flat.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 9,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"18 jun 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 10,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences, Inc.(NasdaqGS: CAI) added to NASDAQ Composite Index\",\n      \"source\": \"MarketScreener\",\n      \"date\": \"hace 1 mes\",\n      \"url\": \"https://www.marketscreener.com/quote/stock/CARIS-LIFE-SCIENCES-INC-190389952/news/Caris-Life-Sciences-Inc-NasdaqGS-CAI-added-to-NASDAQ-Composite-Index-50295384/\",\n      \"full_content\": \"Caris Life Sciences, Inc. has been added in the NASDAQ Composite Index. \\u00a9 S&P Capital IQ - 2025 Share Latest news about Caris Life Sciences, Inc.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 11,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 12,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 13,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 14,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 15,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 16,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 17,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 18,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 19,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 20,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 21,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 22,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 23,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 24,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 25,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 26,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 27,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 28,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 29,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 30,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 31,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 32,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 33,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 34,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 35,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 36,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 37,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 38,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 39,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 40,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 41,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 42,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 43,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 44,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 45,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 46,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 47,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 48,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 49,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 50,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    }\n  ]\n}\n```\n",
        "fundamentals_report": "\ud83d\udcca FUNDAMENTALS ANALYSIS: CAI\n\u26a1 Data fetched in 1.664s (Ultra-Fast Mode)\n============================================================\n\n\ud83c\udfe2 COMPANY PROFILE:\n  Name: Caris Life Sciences Inc\n  Industry: Biotechnology\n  Market Cap: $9,533M\n  Share Outstanding: 278M\n\n\ud83d\udcc8 KEY VALUATION METRICS:\n  P/E Ratio: N/A\n  P/B Ratio: N/A\n  EV/EBITDA: N/A\n  ROE: N/A\n  ROA: N/A\n  Debt/Equity: N/A\n\n\ud83c\udfaf PRICE TARGETS:\n  Current: $34.28\n  Mean Target: $41.14\n  Low Target: $37.71\n  High Target: $44.56\n  Analysts: 10\n\n============================================================\n\ud83d\udd0d FUNDAMENTAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed fundamentals\n  \u2705 Data fetched successfully\n\n\u26a1 Report generated 2025-08-13 18:50:18"
      },
      "risky_history": "Risky Analyst: From an aggressive risk perspective, CAI offers an enticing opportunity in a high\u2010growth, high\u2010volatility biotech environment. Here\u2019s why taking on the associated risks can be attractive and how you can position yourself to maximize returns while managing downside exposure:\n\n1. High\u2013Reward Opportunities and Growth Potential  \n\u2003\u2022 CAI sits at the nexus of cutting-edge precision oncology, with strong developments (new clinical data, favorable regulatory signals, and high-profile index inclusion) that can drive rapid growth.  \n\u2003\u2022 Analysts\u2019 mean target of approximately $41 and a potential high target near $44.56 represent significant upside from the current $34.28 level.  \n\u2003\u2022 The positive social media sentiment and robust IPO performance underline an energetic investor base ready to propel the stock higher, especially if key catalysts (quarterly earnings surprises or breakthroughs in clinical studies) come to fruition.\n\n2. Why the Risks Are Worth Taking  \n\u2003\u2022 Aggressive investors thrive in environments where volatility is a by-product of exponential growth potential\u2014in CAI\u2019s case, the biotech sector frequently rewards risk with outsized gains.  \n\u2003\u2022 While fundamentals currently signal a mixed \u201chold,\u201d the momentum and near-term growth catalysts (e.g., innovative research outcomes and regulatory developments) can flip the narrative quickly.  \n\u2003\u2022 The price inflection point around the $33\u2013$33.50 level offers a tactical entry that enhances the probability of capturing such upside, even if near-term fluctuations exist.\n\n3. Potential Upside Scenarios  \n\u2003\u2022 A robust quarterly earnings report or breakthrough in clinical protocols could trigger a sharp rally, compressing risk-reward ratios as the stock moves toward or exceeds the mean target.  \n\u2003\u2022 Continued bullish sentiment on platforms like StockTwits adds momentum that can accelerate upward price action in the short to medium term.  \n\u2003\u2022 Successful navigation of regulatory hurdles and inclusion in indices are likely to drive institutional buying and boost valuations further, potentially taking CAI into the mid-$40s or beyond.\n\n4. Risk Mitigation Strategies for Aggressive Positions  \n\u2003\u2022 Position Sizing and Staged Entries: Limit your total exposure to 5\u201310% of your portfolio and build in increments near dips (targeting the $33\u2013$33.50 area) to benefit from improved entry points while not overcommitting on one move.  \n\u2003\u2022 Protective Hedges: Use protective puts or implement a call-spread strategy on about 10\u201320% of your CAI position. This hedge provides downside cushioning without completely sacrificing the ability to reap significant upside.  \n\u2003\u2022 Stop-Loss Discipline: Set a stop-loss order around 10% below your entry price (approximately $30) to cap losses if market conditions deteriorate unexpectedly.  \n\u2003\u2022 Continuous Monitoring: Stay alert to quarterly results, regulatory updates, and changes in market sentiment so you can adjust your hedges and position size as needed.\n\nIn summary, despite near-term uncertainties, an aggressive investor can view CAI as a compelling candidate for substantial upside due to its growth catalysts and market sentiment. With a disciplined entry strategy and robust risk management tactics, the risks become an acceptable price to pay for capturing the stock\u2019s transformative potential.",
      "current_safe_response": "Below is a conservative risk perspective for the Caris Life Sciences (CAI) plan with an emphasis on protecting existing capital, identifying potential extreme downside scenarios, and outlining measures to help cushion losses if the market does not perform as expected.\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Avoid taking on an oversized position in CAI. A conservative investor should adhere to the recommendation of allocating only 5\u201310% of the overall portfolio to CAI. This limits exposure if near\u2010term catalysts turn negative.\n\n\u2003\u2022 Consider a staggered entry to minimize the risk of buying in at an overvalued level. Accumulating the position over time\u2014especially waiting for dips near the $33\u2013$33.50 range versus the current price of about $34.28\u2014can provide a margin of safety.\n\n\u2003\u2022 Put emphasis on using a defined exit plan. An appropriate stop\u2010loss located at roughly 10% below the entry price (around $30\u2013$30.50) can help control potential losses before they erode the portfolio too much.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Regulatory and Clinical Setbacks: In the biotech sector, unexpected clinical trial failures or regulatory delays can lead to abrupt re-ratings. This represents a significant tail risk that could drive the stock lower.\n\n\u2003\u2022 Short-term Volatility: Near-term pressures, such as a potential short squeeze or adverse market sentiment shifts (especially if earnings or updates turn out to be disappointing), may trigger a steep and accelerated price decline.\n\n\u2003\u2022 Broader Market or Biotech Downturn: If the whole biotech sector or broader equity markets experience a correction, CAI could be impacted further. A market environment with heightened risk aversion could worsen losses.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Hedging Part of the Position: Consider hedging 10\u201320% of the CAI position using protective puts, call spreads, or even a small short position in a correlated biotech ETF. This approach can help offset losses if the stock moves sharply in the wrong direction.\n\n\u2003\u2022 Regular Monitoring and Updates: Maintain close attention to quarterly results, regulatory news, and any changes in technical indicators. Be prepared to tighten stop-loss measures or adjust hedges if new information significantly impacts the risk outlook.\n\n\u2003\u2022 Option Strategies: Use options that allow you to protect downside risk without completely sacrificing participation in any upside potential. For example, buying modestly priced put options can act as an insurance policy while limiting further downside drag if the stock falls below expected levels.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Allocate Conservatively: Restrict your overall exposure in CAI to no more than 5\u201310% of the portfolio. This limits potential losses if the stock were to decline.\n \n\u2003\u2022 Incremental Entries: Instead of a single lump sum purchase, consider dividing the intended allocation into smaller portions. This staged entry strategy reduces the risk of buying an entire position at a relatively high price level. \n\n\u2003\u2022 Position Adjustments: If market conditions worsen or if technical fundamentals deteriorate further, consider reducing the position size gradually to lock in capital. Adjusting the hedge ratio on your position is also key as the stock price moves.\n\nIn summary, from a conservative risk management point of view, your main focus should be on protecting capital by limiting exposure, actively hedging a fraction of the position, and setting discipline in executing stop-loss measures. By doing so, you maintain a controlled risk profile in a dynamic and sometimes volatile biotech sector while still participating in a potential long-term upside if CAI meets its clinical or market milestones.",
      "safe_history": "Safe Analyst: Below is a conservative risk perspective for the Caris Life Sciences (CAI) plan with an emphasis on protecting existing capital, identifying potential extreme downside scenarios, and outlining measures to help cushion losses if the market does not perform as expected.\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Avoid taking on an oversized position in CAI. A conservative investor should adhere to the recommendation of allocating only 5\u201310% of the overall portfolio to CAI. This limits exposure if near\u2010term catalysts turn negative.\n\n\u2003\u2022 Consider a staggered entry to minimize the risk of buying in at an overvalued level. Accumulating the position over time\u2014especially waiting for dips near the $33\u2013$33.50 range versus the current price of about $34.28\u2014can provide a margin of safety.\n\n\u2003\u2022 Put emphasis on using a defined exit plan. An appropriate stop\u2010loss located at roughly 10% below the entry price (around $30\u2013$30.50) can help control potential losses before they erode the portfolio too much.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Regulatory and Clinical Setbacks: In the biotech sector, unexpected clinical trial failures or regulatory delays can lead to abrupt re-ratings. This represents a significant tail risk that could drive the stock lower.\n\n\u2003\u2022 Short-term Volatility: Near-term pressures, such as a potential short squeeze or adverse market sentiment shifts (especially if earnings or updates turn out to be disappointing), may trigger a steep and accelerated price decline.\n\n\u2003\u2022 Broader Market or Biotech Downturn: If the whole biotech sector or broader equity markets experience a correction, CAI could be impacted further. A market environment with heightened risk aversion could worsen losses.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Hedging Part of the Position: Consider hedging 10\u201320% of the CAI position using protective puts, call spreads, or even a small short position in a correlated biotech ETF. This approach can help offset losses if the stock moves sharply in the wrong direction.\n\n\u2003\u2022 Regular Monitoring and Updates: Maintain close attention to quarterly results, regulatory news, and any changes in technical indicators. Be prepared to tighten stop-loss measures or adjust hedges if new information significantly impacts the risk outlook.\n\n\u2003\u2022 Option Strategies: Use options that allow you to protect downside risk without completely sacrificing participation in any upside potential. For example, buying modestly priced put options can act as an insurance policy while limiting further downside drag if the stock falls below expected levels.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Allocate Conservatively: Restrict your overall exposure in CAI to no more than 5\u201310% of the portfolio. This limits potential losses if the stock were to decline.\n \n\u2003\u2022 Incremental Entries: Instead of a single lump sum purchase, consider dividing the intended allocation into smaller portions. This staged entry strategy reduces the risk of buying an entire position at a relatively high price level. \n\n\u2003\u2022 Position Adjustments: If market conditions worsen or if technical fundamentals deteriorate further, consider reducing the position size gradually to lock in capital. Adjusting the hedge ratio on your position is also key as the stock price moves.\n\nIn summary, from a conservative risk management point of view, your main focus should be on protecting capital by limiting exposure, actively hedging a fraction of the position, and setting discipline in executing stop-loss measures. By doing so, you maintain a controlled risk profile in a dynamic and sometimes volatile biotech sector while still participating in a potential long-term upside if CAI meets its clinical or market milestones.",
      "count": 2,
      "judge_decision": "After weighing the technical neutrality and mixed fundamentals against the strong bullish sentiment, healthy analyst price targets, and attractive entry levels relative to near-term dips, our risk-adjusted strategy calls for a long position\u2014but with a modest allocation and partial hedging to protect against near\u2010term volatility and structural risks in the biotech sector.\n\nKey points:\n\u2022 The technical setup suggests waiting for a dip to around $33\u2013$33.50, which combined with bullish sentiment and a mean target near $41, offers a favorable risk/reward.\n\u2022 A moderate position size (about 5\u201310% of the portfolio) limits exposure, while a modest hedge (approximately 10\u201320% of the CAI position via options or correlated ETF) protects against an abrupt downturn.\n\u2022 Although fundamentals are mixed, potential catalysts such as positive quarterly results, clinical breakthroughs, and regulatory progress support the longer\u2010term upside.\n\nThus, our final trading decision is to BUY CAI\u2014with careful incremental entries and risk hedging in place.\n\nFINAL DECISION: BUY",
      "parallel_execution": true,
      "neutral_history": "Neutral Analyst: Below is a balanced risk perspective on the CAI investment plan, using an objective approach and data-driven analysis.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Objective Risk-Reward Analysis\n\n\u2022 Upside:  \n\u2003\u2013 The plan aims to capture a potential move from an entry target near $33\u2013$33.50 up to a mean target of about $41. This offers an approximate 20%\u201325% potential gain on a dip\u2010entry compared with current levels (~$34.28).  \n\u2003\u2013 Positive market sentiment\u2014both on StockTwits and Twitter\u2014coupled with a relatively strong technical rally around IPO levels, adds to the upside case if catalysts (better than expected earnings or new clinical/regulatory developments) materialize.\n\n\u2022 Downside:  \n\u2003\u2013 Technical signals are mixed (\u201cHOLD\u201d) and the fundamentals are in a neutral state (with many valuation metrics not widely available), which suggests that near-term volatility is likely.  \n\u2003\u2013 The presence of structural risks (regulatory setbacks, disappointing clinical outcomes or management shifts) and broader market pressures in biotech can act as significant headwinds.  \n\u2003\u2013 The plan recommends a stop\u2010loss roughly 10% below the entry price (~$30\u2013$30.50), indicating that a move of that magnitude would be considered a risk event.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Balanced Position Sizing Recommendations\n\n\u2022 Recommended allocation is 5\u201310% of the overall portfolio. This moderate size helps ensure that if near-term risks materialize, the adverse impact on total portfolio performance is limited.  \n\u2022 Given the uncertainty inherent in near-term earnings and catalyst risk, hedging a small portion (about 10\u201320% of the CAI position) with options or a correlated biotech ETF short provides an extra layer of downside protection.  \n\u2022 Staged entries rather than lump-sum buying are advisable to capture dips and potentially average into positions if volatility persists.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Positive Scenario (Catalysts Confirm Upside):  \n\u2003\u2013 If quarterly earnings or regulatory/clinical updates exceed expectations and market sentiment remains bullish, it would be wise to gradually lift stop-losses upward and reduce hedge levels.  \n\u2003\u2013 In this case, increasing exposure later on (if further technical momentum develops beyond \u201cHOLD\u201d) can help capture additional upside.\n\n\u2022 Negative Scenario (Catalysts Trigger Caution):  \n\u2003\u2013 Should there be disappointing disclosures, regulatory setbacks, or broad biotech weakness, the stop-loss at about 10% below your entry will help limit losses.  \n\u2003\u2013 Under such conditions, further tightening hedges or even reducing the CAI position may be warranted to avoid deeper drawdowns.\n\n\u2022 Neutral Scenario:  \n\u2003\u2013 With mixed technical indicators and fundamentals in a \u201chold\u201d state, a measured, phased entry can help avoid being caught on the wrong side of volatility.  \n\u2003\u2013 Monitoring technical breaks from consolidation areas along with sentiment and news flows will inform the timing of subsequent entries or a decision to pause additional buying.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Data-Driven, Unbiased Recommendations\n\n\u2022 The current data indicate that while bullish sentiment and mean price targets provide a compelling case to \u201cbuy,\u201d structural uncertainties and near-term volatility call for caution.  \n\u2022 Following chart signals, planned entries near $33\u2013$33.50 improve the risk/reward ratio relative to potential stop-loss levels, and a diversified portfolio allocation (5\u201310% total) helps minimize exposure.  \n\u2022 Using a conditional hedging strategy (e.g., protective options) allows for capitalizing on upside potential while mitigating downside risk if adverse catalysts unfold.  \n\u2022 Ultimately, investors should stay flexible\u2014monitor quarterly results, regulatory news, and broader market conditions\u2014to adjust position sizing, hedges, or exit strategies accordingly.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nConclusion\n\nTaking into account the combined technical, sentiment, and fundamental data, an investor could consider a \u201cbuy-with-hedge\u201d approach for CAI. This approach is supported by planning a moderate allocation (5\u201310% of the portfolio), using staggered entries at dips near $33\u2013$33.50, and placing protective measures (such as stop-loss orders and partial hedges) to guard against near-term volatility or adverse news. This balanced, data-driven plan helps to capture the potential upside while limiting exposure should risks materialize.",
      "debate_start_time": 110661.525148291
    },
    "research_debate_state": {
      "current_round": 2,
      "max_rounds": 1,
      "consensus_reached": false,
      "judge_feedback": "",
      "debate_history": [
        {
          "round": 1,
          "bull": "By addressing the bear\u2019s concerns head on and emphasizing that our growth and technical indicators reflect latent value not yet fully captured by conventional metrics, we believe CAI stands as a strong, margin\u2010of\u2010safety buy in today\u2019s dynamic biotech arena.",
          "bear": "With our SELL WITH HEDGE recommendation at a 78/100 conviction score, we acknowledge the near-term risk of a short squeeze but remain firmly positioned for a re-rating downward based on fundamental and structural risks. We advise close monitoring of quarterly disclosures, management updates, and regulatory signals to adjust or exit our shorts as the market\u2019s narrative begins to align with hard data."
        }
      ]
    },
    "investment_plan": "Below is our comprehensive investment plan for Caris Life Sciences Inc (CAI), derived from a synthesis of technical data, fundamentals, sentiment, and the final debate positions.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Investment Recommendation  \n\u2022 Recommendation: BUY, but with a partial hedge.  \n\u2022 Confidence Level: Moderately bullish (~70/100) given the strong sentiment and upside price targets, while acknowledging near\u2010term uncertainties raised by our bearish counterpart.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Position Sizing  \n\u2022 Recommended Allocation: 5\u201310% of your portfolio.  \n\u2022 Rationale: Given the mixed fundamental \u201chold\u201d signal and technical neutrality combined with bullish sentiment, a moderate allocation minimizes exposure if near\u2010term risks materialize.  \n\u2022 Hedge: Use options or a short position in a correlated biotech ETF on a small portion (e.g., 10\u201320% of the CAI position) to protect against a sudden downside move.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Entry Strategy  \n\u2022 Target Entry Price: Aim to accumulate positions on dips around $33\u2013$33.50\u2014just below the current price of $34.28\u2014to improve yield of potential upside.  \n\u2022 Entry Conditions:  \n\u2003\u2013 Look for an intraday pullback or consolidation area before a breakout higher.  \n\u2003\u2013 Confirm with any renewed technical momentum (attempting to shift from \u201chold\u201d to \u201cbuy\u201d indicators).  \n\u2013 Alternatively, consider staged entries rather than a lump sum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Risk Management  \n\u2022 Stop-Loss Level: Set a stop-loss around 10% below the entry price (approximately $30\u2013$30.50) to limit losses if fundamentals or market sentiment shift negatively.  \n\u2022 Hedging:  \n\u2003\u2013 Implement a protective put or a call spread hedge on a portion of your CAI position to guard against near-term volatility.  \n\u2003\u2013 Monitor short-term technical signals and quarterly disclosure updates to adjust the hedge as needed.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n5. Time Horizon  \n\u2022 Medium-Term Outlook: Hold for a period of several weeks to a few months.  \n\u2022 Rationale: This horizon captures potential upward moves toward the mean target of ~$41 while allowing time to assess quarterly results and regulatory updates before any longer-term re-rating.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n6. Key Catalysts  \n\u2022 Positive Quarterly Earnings: Better-than-expected outlook or growth news could fuel further buying.  \n\u2022 Regulatory or Clinical Developments: Progress in precision oncology therapies that validate CAI\u2019s technology.  \n\u2022 Continued Positive Market Sentiment: Sustained bullish engagement on platforms like StockTwits or favorable analyst upgrades may support upward price movement.  \n\u2022 Index Inclusion: Having been added to the NASDAQ Composite Index may steadily enhance liquidity and investor attention.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n7. Major Risks  \n\u2022 Structural and Fundamental Risks: Regulatory setbacks, disappointing clinical trial outcomes, or management changes could trigger a re-rating downward.  \n\u2022 Near-Term Volatility: The bearish argument warns of a short squeeze and near-term pressures; adverse quarterly disclosures may accelerate selling.  \n\u2022 Market Environment: A broader biotech slowdown or shifts in market risk sentiment could impose downside risk.\n  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n8. Synthesis and Final Decision  \n\u2022 Bull Perspective: Emphasizes that CAI\u2019s latent value and a strong margin of safety\u2014supported by a mean target of ~$41 and an overall bullish sentiment score\u2014make it an attractive buy in today\u2019s dynamic biotech sector.  \n\u2022 Bear Perspective: Cautions that near-term risks (such as potential short squeezes and structural concerns) justify using hedges and cautious position sizing.  \n\u2022 Final Decision: By blending these views, our strategy is to go long on CAI with a \u201cbuy-with-hedge\u201d approach. This allows you to participate in the upside suggested by bullish sentiment and technical targets while protecting downside risk in case near-term catalysts go against expectations.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nActionable Summary:  \n\u2022 Initiate a 5\u201310% portfolio allocation in CAI, entering incrementally at dips around $33\u2013$33.50.  \n\u2022 Place a stop-loss near $30 to control risk and hedge a fraction (10\u201320% of the position) with options to safeguard against volatility.  \n\u2022 Maintain a medium-term view (a few weeks to months) and closely monitor quarterly results, regulatory updates, and market sentiment for adjustments.\n\nThis balanced, tactical plan seeks to capture potential appreciation while cushioning the portfolio from near-term structural uncertainties.",
    "trader_investment_plan": "Below is our comprehensive investment plan for Caris Life Sciences Inc (CAI), derived from a synthesis of technical data, fundamentals, sentiment, and the final debate positions.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n1. Investment Recommendation  \n\u2022 Recommendation: BUY, but with a partial hedge.  \n\u2022 Confidence Level: Moderately bullish (~70/100) given the strong sentiment and upside price targets, while acknowledging near\u2010term uncertainties raised by our bearish counterpart.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n2. Position Sizing  \n\u2022 Recommended Allocation: 5\u201310% of your portfolio.  \n\u2022 Rationale: Given the mixed fundamental \u201chold\u201d signal and technical neutrality combined with bullish sentiment, a moderate allocation minimizes exposure if near\u2010term risks materialize.  \n\u2022 Hedge: Use options or a short position in a correlated biotech ETF on a small portion (e.g., 10\u201320% of the CAI position) to protect against a sudden downside move.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n3. Entry Strategy  \n\u2022 Target Entry Price: Aim to accumulate positions on dips around $33\u2013$33.50\u2014just below the current price of $34.28\u2014to improve yield of potential upside.  \n\u2022 Entry Conditions:  \n\u2003\u2013 Look for an intraday pullback or consolidation area before a breakout higher.  \n\u2003\u2013 Confirm with any renewed technical momentum (attempting to shift from \u201chold\u201d to \u201cbuy\u201d indicators).  \n\u2013 Alternatively, consider staged entries rather than a lump sum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n4. Risk Management  \n\u2022 Stop-Loss Level: Set a stop-loss around 10% below the entry price (approximately $30\u2013$30.50) to limit losses if fundamentals or market sentiment shift negatively.  \n\u2022 Hedging:  \n\u2003\u2013 Implement a protective put or a call spread hedge on a portion of your CAI position to guard against near-term volatility.  \n\u2003\u2013 Monitor short-term technical signals and quarterly disclosure updates to adjust the hedge as needed.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n5. Time Horizon  \n\u2022 Medium-Term Outlook: Hold for a period of several weeks to a few months.  \n\u2022 Rationale: This horizon captures potential upward moves toward the mean target of ~$41 while allowing time to assess quarterly results and regulatory updates before any longer-term re-rating.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n6. Key Catalysts  \n\u2022 Positive Quarterly Earnings: Better-than-expected outlook or growth news could fuel further buying.  \n\u2022 Regulatory or Clinical Developments: Progress in precision oncology therapies that validate CAI\u2019s technology.  \n\u2022 Continued Positive Market Sentiment: Sustained bullish engagement on platforms like StockTwits or favorable analyst upgrades may support upward price movement.  \n\u2022 Index Inclusion: Having been added to the NASDAQ Composite Index may steadily enhance liquidity and investor attention.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n7. Major Risks  \n\u2022 Structural and Fundamental Risks: Regulatory setbacks, disappointing clinical trial outcomes, or management changes could trigger a re-rating downward.  \n\u2022 Near-Term Volatility: The bearish argument warns of a short squeeze and near-term pressures; adverse quarterly disclosures may accelerate selling.  \n\u2022 Market Environment: A broader biotech slowdown or shifts in market risk sentiment could impose downside risk.\n  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \n8. Synthesis and Final Decision  \n\u2022 Bull Perspective: Emphasizes that CAI\u2019s latent value and a strong margin of safety\u2014supported by a mean target of ~$41 and an overall bullish sentiment score\u2014make it an attractive buy in today\u2019s dynamic biotech sector.  \n\u2022 Bear Perspective: Cautions that near-term risks (such as potential short squeezes and structural concerns) justify using hedges and cautious position sizing.  \n\u2022 Final Decision: By blending these views, our strategy is to go long on CAI with a \u201cbuy-with-hedge\u201d approach. This allows you to participate in the upside suggested by bullish sentiment and technical targets while protecting downside risk in case near-term catalysts go against expectations.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500  \nActionable Summary:  \n\u2022 Initiate a 5\u201310% portfolio allocation in CAI, entering incrementally at dips around $33\u2013$33.50.  \n\u2022 Place a stop-loss near $30 to control risk and hedge a fraction (10\u201320% of the position) with options to safeguard against volatility.  \n\u2022 Maintain a medium-term view (a few weeks to months) and closely monitor quarterly results, regulatory updates, and market sentiment for adjustments.\n\nThis balanced, tactical plan seeks to capture potential appreciation while cushioning the portfolio from near-term structural uncertainties.",
    "final_trade_decision": "FINAL DECISION: BUY CAI\n\nBelow is the execution plan incorporating market microstructure analysis, order management, risk controls, and our investment thesis:\n\n1. Entry & Order Execution Strategy  \n\u2003a. Incremental Buy via Aggressive Limit Orders with Algorithmic Slicing  \n\u2003\u2003\u2022 Primary Order: Deploy ~60% of the total CAI allocation incrementally using aggressive limit orders, targeting entry in the $33.00\u2013$33.50 window.  \n\u2003\u2003\u2003\u2013 Instruction: When CAI dips to between $33.00 and $33.50, immediately submit a limit order at $33.50 (or better if the market clears lower) for 60% of our targeted position size.  \n\u2003\u2003\u2003\u2013 Rationale: Capture the dip below the current $34.28 price for improved yield while protecting against overpaying.  \n\u2003\u2003\u2022 Secondary Orders: For the remaining 40% of the targeted allocation, employ a time-weighted average price (TWAP)/VWAP algorithm over a 60\u201390 minute window if liquidity remains sufficient, ensuring a smooth fill without undue market impact.  \n\u2003\u2003\u2003\u2013 This helps guard against slippage if immediate liquidity is lacking.\n\n2. Order Details & Sizing  \n\u2003\u2022 Target Allocation: 5\u201310% of the overall portfolio in CAI. (Exact number of shares to be calibrated against live market volume.)  \n\u2003\u2022 Example Setup (for illustration):  \n\u2003\u2003\u2013 Total Target: 1,000 shares  \n\u2003\u2003\u2003\u25cb Primary aggressive entry: 600 shares via limit order at $33.50 (triggered if price touches the dip zone)  \n\u2003\u2003\u2003\u25cb Secondary algorithmic clipping: 400 shares via VWAP/TWAP over the subsequent 60\u201390 minutes if conditions remain favorable  \n\u2003\u2022 Order Types:  \n\u2003\u2003\u2013 For primary fills, use limit orders set at $33.50 to ensure price control.  \n\u2003\u2003\u2013 For the residual, use a TWAP/VWAP algorithm to blend into the market liquidity.\n\n3. Risk Controls  \n\u2003\u2022 Pre-trade Checks: Confirm current bid/ask spread tightness, order book depth, and immediate volume before initiating orders.  \n\u2003\u2022 Stop-Loss: Establish a stop-loss order at approximately $30.00 (around 10% below the target entry price) to limit potential downside risk.  \n\u2003\u2022 Slippage & Abort Conditions:  \n\u2003\u2003\u2013 Set a maximum tolerated slippage threshold (e.g., 0.5\u20131.0% from the limit price).  \n\u2003\u2003\u2013 If the market begins to exhibit sizeable adverse moves or unusual volatility beyond predetermined levels, pause further executions and reassess.\n\u2003\u2022 Hedge Implementation:  \n\u2003\u2003\u2013 Simultaneously, initiate a protective hedge covering roughly 10\u201320% of the CAI position.  \n\u2003\u2003\u2013 Hedge can be executed via options (e.g., buying protective puts at strike levels near $33 to $33.50) or by taking a modest short position in a correlated biotech ETF.\n\n4. Monitoring Plan  \n\u2003\u2022 Real-Time Tracking: Monitor order fills, slippage, and real-time market depth updates.  \n\u2003\u2022 Price Alerts: Set alerts for price rebounds, deteriorations, or if prices breach the stop-loss threshold.  \n\u2003\u2022 Partial Fill Management: Should any order only partially fill, resume incremental buying if the mid-price remains within the acceptable window.  \n\u2003\u2022 Post-Execution Review: Once the full position is executed (or the order is aborted due to market changes), review overall positioning in light of evolving quarterly reports, regulatory updates, and sentiment shifts.\n\n5. Execution Timeframe and Confidence  \n\u2003\u2022 Time Horizon: Execute the initial order(s) throughout a short-term window (approximately 60\u201390 minutes) following confirmation of a dip near the $33\u2013$33.50 range.  \n\u2003\u2022 Confidence Level: Moderately bullish (~70/100) based on the combined technical, fundamental, and sentiment analysis. This approach balances participation in the upside while guarding against near-term volatility and fundamental uncertainties.\n\nRationale Summary:  \nThe plan captures CAI\u2019s favorable risk/reward when it dips below the current level, in line with our technical and sentiment signals. The staged entry via aggressive limit orders and TWAP/VWAP algorithms minimizes market impact, while the protective hedge and disciplined stop-loss provide controlled downside risk.\n\nExecute as outlined for CAI with BUY as the final decision, ensuring tactical entry and risk management throughout the process.",
    "processed_signal": "BUY"
  }
}